Joint Formulary & PAD

Linagliptin - Diabetes Mellitus

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important
Sitagliptin is 1st line. Only consider linagliptin in patients with rapidly deteriorating renal function where there is a risk that dose reduction of sitagliptin may not take place.

PAD Profile

ChemicalSubstance :
Linagliptin
Indication :
Diabetes Mellitus
Group Name :
DPP-4s
Keywords :
Gliptins, DPP-4, Dipeptylpeptidase -4 inhibitor, Type II
Brand Names Include :
Trajenta
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Committee Recommendations (1)

The Surrey Heartlands Area Prescribing Committee recommend:

sitagliptin (prescribed generically) as the preferred gliptin (DPP4) - GREEN traffic light status

Linagliptin RESTRICTED USE - as an option in patients with deteriorating renal function where there is a risk that dose reduction of sitagliptin may not take place

Other gliptins (alogliptin, vildagliptin, saxagliptin) should NOT BE INITIATED in new patients

Other Indications

Below are listed other indications that Linagliptin is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Diabetes Mellitus.